Yeh K H, Yeh S H, Hsu C H, Wang T M, Ma I F, Cheng A L
Department of Oncology, National Taiwan University Hospital, 7 Chung-Shan South Road, Tapei 100, Taiwan.
Br J Cancer. 2000 Dec;83(11):1510-5. doi: 10.1054/bjoc.2000.1456.
We have recently demonstrated that HDFL (high-dose 5-FU 2600 mg m-2 week-1 and leucovorin 500 mg m-2 week-1, weekly 24-h infusion) is highly active in the treatment of gastric cancer. To further clarify the possible mechanism underlying the improved activity of HDFL compared with conventional 5-FU regimens, we conducted in vitro studies examining the effect of these regimens on the differential regulation of thymidylate synthase (TS) in NCI-N87, a human gastric cancer cell line. The expected serum concentrations of 5-FU are 100-200 mM (lasting for less than 30 min) and 5-10 mM (lasting for 24 h) for the conventional 5-FU regimens (bolus injection or short intravenous infusion of 5-FU 370-500 mg m-2) and the HDFL regimens, respectively. Western blot analysis revealed that 24-h exposure of NCI-N87 to 2.5-10.0 mM of 5-FU resulted in a dose-dependent depletion of free TS, lasting for more than 24 h. In contrast, 30-min exposure of NCI-N87 to 200 mM of 5-FU resulted in a less than 12-h depletion of free TS. Moreover, 24-h exposure to 5-FU resulted in a higher S-phase blockade and enhanced cytotoxicity. In both modes of 5-FU treatment, the initial rapid depletion of free TS was accompanied by a rapid increment of a higher-molecular-weight TS molecule, suggesting that rapid formation of the ternary complex was the key mechanism of 5-FU action during this period. Northern blot analysis showed that the steady-state mRNA of TS was not affected by either of the schedules. We conclude that 24-h exposure of gastric cancer cells to low concentration of 5-FU resulted in better suppression of free TS, a higher degree of S-phase blockade, and enhanced cytotoxicity compared to 30-min exposure to high concentration of 5-FU. These in vitro results may help explain the improved clinical efficacy of HDFL regimens compared to conventional 5-FU regimens.
我们最近证明,高剂量氟尿嘧啶(HDFL,2600mg/m²每周一次,亚叶酸钙500mg/m²每周一次,每周24小时静脉输注)在胃癌治疗中具有高度活性。为了进一步阐明与传统氟尿嘧啶方案相比,HDFL活性提高的潜在机制,我们进行了体外研究,考察这些方案对人胃癌细胞系NCI-N87中胸苷酸合成酶(TS)差异调节的影响。对于传统氟尿嘧啶方案(氟尿嘧啶370-500mg/m²推注或短时间静脉输注)和HDFL方案,氟尿嘧啶的预期血清浓度分别为100-200μM(持续时间小于30分钟)和5-10μM(持续24小时)。蛋白质印迹分析显示,NCI-N87细胞在2.5-10.0μM氟尿嘧啶中暴露24小时导致游离TS剂量依赖性减少,持续超过24小时。相比之下,NCI-N87细胞在200μM氟尿嘧啶中暴露30分钟导致游离TS减少不到12小时。此外,暴露于氟尿嘧啶24小时导致更高的S期阻滞和增强的细胞毒性。在两种氟尿嘧啶治疗模式中,游离TS的初始快速减少伴随着高分子量TS分子的快速增加,这表明在此期间三元复合物的快速形成是氟尿嘧啶作用的关键机制。Northern印迹分析表明,TS的稳态mRNA不受任何一种给药方案的影响。我们得出结论,与暴露于高浓度氟尿嘧啶30分钟相比,胃癌细胞暴露于低浓度氟尿嘧啶24小时可更好地抑制游离TS,更高程度地阻滞S期,并增强细胞毒性。这些体外研究结果可能有助于解释HDFL方案与传统氟尿嘧啶方案相比临床疗效提高的原因。